Combination

Acri Capital Acquisition Corporation Announces Definitive Business Combination Agreement with Foxx Development Inc.

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Second Continental Congress, ACAC, Register, Internet of things, Combination, Electronics, Combined, Congress, LLP, Tablet, Research, Environment, Partnership, Security (finance)

Austin, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (NASDAQ: ACAC) (“Acri” or “ACAC”), a Delaware incorporated special purpose acquisition company listed on the Nasdaq Global Market, and Foxx Development Inc. (“Foxx”), a Texas based consumer electronics and integrated Internet-of-Things (IoT) solution company, today announced that they have entered into a definitive business combination agreement (the “Business Combination Agreement”) pursuant to which a newly established subsidiary of Acri will become a publicly listed company combining Acri and Foxx (the “Combined Company”) upon the closing of the transaction contemplated therein (the “Proposed Transaction”).

Key Points: 
  • Austin, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (NASDAQ: ACAC) (“Acri” or “ACAC”), a Delaware incorporated special purpose acquisition company listed on the Nasdaq Global Market, and Foxx Development Inc. (“Foxx”), a Texas based consumer electronics and integrated Internet-of-Things (IoT) solution company, today announced that they have entered into a definitive business combination agreement (the “Business Combination Agreement”) pursuant to which a newly established subsidiary of Acri will become a publicly listed company combining Acri and Foxx (the “Combined Company”) upon the closing of the transaction contemplated therein (the “Proposed Transaction”).
  • Foxx, established in 2017 as a Texas incorporated company, is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients.
  • In this context, Foxx is an ideal fit, aligning with our criteria.” said “Joy” Yi Hua, CEO and Chairwoman of Acri.
  • EF Hutton LLC is serving as capital markets advisor to Acri, and Robinson & Cole LLP is serving as legal counsel to Acri.

Development of Combination Products: Critical Interactions Training Course (ONLINE EVENT) - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024
Education, Training, Pharmaceutical, Health, CTD, GMP, Combination

The "Development of Combination Products: Critical Interactions Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Development of Combination Products: Critical Interactions Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • The programme will cover the regulatory strategy to adopt and the relevant aspects of GMP and quality processes, including the data expectations for the CTD.
  • Drug/device and device/drug combination products are becoming increasingly important in the medical industry.
  • The development and manufacture of these products raises a number of complex issues and the quality and regulatory aspects are challenging.

Altitude Acquisition Corp. Announces Extension of Deadline to Complete Initial Business Combination

Retrieved on: 
Wednesday, February 7, 2024
ALTU, Altitude, Combination

ATLANTA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Altitude Acquisition Corp. (Nasdaq: ALTUU, ALTU, ALTUW) (“Altitude”), announced today that its board of directors (the “Board”) has extended the date by which Altitude must consummate an initial business combination (the “Deadline Date”) for an additional month, from February 11, 2024 to March 11, 2024.

Key Points: 
  • ATLANTA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Altitude Acquisition Corp. (Nasdaq: ALTUU, ALTU, ALTUW) (“Altitude”), announced today that its board of directors (the “Board”) has extended the date by which Altitude must consummate an initial business combination (the “Deadline Date”) for an additional month, from February 11, 2024 to March 11, 2024.
  • Altitude’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”), gives the Board the right to extend the Deadline Date, without further stockholder vote, up to three times for an additional one month each time (each, an “Extension”), from December 11, 2023 to up to March 11, 2024.
  • As previously announced, on April 23, 2023, Altitude entered into a business combination agreement (the “Business Combination Agreement”) with Picard Medical, Inc. (“Picard”) and the other parties thereto, which provides for a business combination between Altitude and Picard.
  • The purpose of this monthly Extension is to provide Altitude with additional time to consummate the proposed business combination with Picard.

LEATT WINS 2024 DESIGN & INNOVATION AWARDS FOR JERSEY MTB ALL MOUNTAIN 5.0 and PANTS MTB ALL MOUNTAIN 4.0

Retrieved on: 
Wednesday, February 7, 2024
Helmet, OTCQB, Clothing, Trousers, Moto, Sensation, Combination, Innovation, MTB, Engineering, Velocity

CAPE TOWN, South Africa, Feb. 7, 2024 /PRNewswire/ -- Leatt Corporation, (OTCQB: LEATT), a leading developer and marketer of head-to-toe protective equipment for Moto, MTB, and a wide range of extreme and high-velocity sports, today announced that it has won the Design & Innovation Award 2024 in the off-road category, for its Jersey MTB All Mountain 5.0 and Pants MTB All Mountain 4.0.

Key Points: 
  • The Design & Innovation Award (DI.A) is considered the benchmark achievement for the bike industry's highest-performing products.
  • "This award is another validation of our engineering and design expertise," said Leatt CEO Sean Macdonald.
  • "We have built an international brand based on the quality and cutting-edge design of our head-to-toe line of innovative products.
  • The Jersey MTB AllMtn 5.0 and Pants MTB AllMtn 4.0, along with all other Leatt products, are featured at www.leatt.com .

Berry Announces First Quarter 2024 Results

Retrieved on: 
Wednesday, February 7, 2024
Packaging, Chemicals, Plastics, Other Manufacturing, Manufacturing, Internet, GLT, Hygiene, Growth, USD, Consumer, Hand, Depreciation, Ratio, Combination, Acquisition, Webcast, Real estate

As previously announced, Berry’s Board of Directors declared a quarterly cash dividend of $0.275 per share payable on March 15, 2024 to stockholders of record as of March 1, 2024.

Key Points: 
  • As previously announced, Berry’s Board of Directors declared a quarterly cash dividend of $0.275 per share payable on March 15, 2024 to stockholders of record as of March 1, 2024.
  • During the first quarter of fiscal 2024, Berry repurchased 106,000 shares for $7 million, leaving $435 million authorized for share repurchases at the end of the first fiscal quarter.
  • Upon the completion of the transaction, Berry is expected to own approximately ninety percent of the newly combined company.
  • (based on information available as of February 7, 2024)
    Cash flow from operations range of $1.35 - $1.45 billion; free cash flow range of $800-$900 million
    The Company will host a conference call today, February 7, 2024, at 10 a.m. U.S. Eastern Time to discuss our first fiscal quarter 2024 results.

Slam Corp. and Lynk Global, Inc. Announce Definitive Business Combination Agreement

Retrieved on: 
Monday, February 5, 2024
Consumer Electronics, Technology, Satellite, Mobile, Wireless, Telecommunications, Networks, File, Security (finance), Growth, Orbit, Register, Lynk Global, Combination, Acquisition, Business analyst, LLP, Form

(“Lynk”), the world’s leading satellite-direct-to-standard-phone (“sat2phone”) telecoms provider, and Slam Corp. (NASDAQ: SLAM), a special purpose acquisition company (“Slam”), today announced that they have entered into a definitive business combination agreement (the “Business Combination Agreement”) under which Slam will combine with Lynk.

Key Points: 
  • (“Lynk”), the world’s leading satellite-direct-to-standard-phone (“sat2phone”) telecoms provider, and Slam Corp. (NASDAQ: SLAM), a special purpose acquisition company (“Slam”), today announced that they have entered into a definitive business combination agreement (the “Business Combination Agreement”) under which Slam will combine with Lynk.
  • Charles Miller added, “Through our proposed business combination with Slam, we believe Lynk will be well-positioned to raise capital through several avenues.
  • Under the terms of the business combination agreement, the transaction values Lynk at a pre-money enterprise value of $800 million.
  • Additional information about the proposed Business Combination will be described in the Registration Statement relating to the proposed Business Combination, which Slam and Lynk Global Holdings, Inc. (“Topco”), a holding company formed to complete the Business Combination, will file with the SEC.

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Retrieved on: 
Thursday, February 1, 2024
Traction, Growth, Umbilical cord, Extracellular matrix, Extremities, Regenerative medicine, Chronic pain, Combination, Collagen, Pelvis, CELU, Cytokine, Knee, Environment, Exosome, FDA, Disorder, Osteoarthritis, Device, Food, Decellularization, Dentistry, Protein, Disability, Chemokine, Sale, Tissue, GMP, Burns, Pharmaceutical industry

FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline. As used here, “net sales” refers exclusively to revenue from the sale of advanced biomaterial products and biobanking services, respectively, and does not include any revenue from other sources such as license fees and royalties or revenue earned under research collaboration agreements.

Key Points: 
  • FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline.
  • “Our sales of advanced biomaterial products grew dramatically in the fourth quarter of 2023 as our newest Biovance 3L product gained traction.
  • The Company expects in future to update expected full year 2024 net sales of its advanced biomaterial product and biobanking businesses.
  • The Company’s advanced biomaterial product pipeline consists of four commercial-stage products and three development-stage product candidates.

Renesas Brings Industry-Leading Performance of RA8 Series MCUs to Motor Control Applications

Retrieved on: 
Tuesday, January 30, 2024
Semiconductor, Consumer Electronics, IOT (Internet of Things), Technology, Other Technology, Artificial Intelligence, Hardware, Cortex, ECC, MCU, Multimedia, BSP, RX, ARM Cortex-M, Renesas Electronics, Family, AI, RL78, Embedded, DSP, CPU, Machine learning, ASSP, Safety, Internet, SPI, Anomaly, Ecosystem, FSP, PWM, Flash, BGA, Automation, RZ, UEFI, SCI, Spacecraft, ARM architecture family, IP, Algorithm, Software, Combination, Arm, Video game

View the full release here: https://www.businesswire.com/news/home/20240130232378/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240130232378/en/
    The RA8T1 group is the third in Renesas’ RA8 Series, all of which deliver breakthrough performance of 6.39 CoreMark/MHz1.
  • These capabilities combined with the advanced timers and Renesas’ power management expertise, enable customers to build comprehensive, low-power motor control solutions.
  • The new MCUs are supported in Renesas’ Flexible Motor Control development kit that enables easy evaluation of motor control using permanent magnet synchronous motors (brushless DC motors), and the Renesas Motor Workbench development tool.
  • This development kit offers a common design platform with numerous Renesas motor control MCUs from the RA and RX families, enabling migration of IP across numerous devices.

ClimateRock and GreenRock Announce Filing of a Registration Statement in Connection with Proposed Business Combination

Retrieved on: 
Monday, January 29, 2024
Farm, Agreement, Combination, Wind, LLP, Business analyst, Business, Prospectus, ESG, Executive, Form F-4, Form, Plan, Growth, Lead, Carbon, Climate change, Acquisition, CLRC, Security (finance), Cayman, Renewable energy

Upon the closing of the business combination between ClimateRock and GreenRock contemplated by the Business Combination Agreement (the “Business Combination”), a holding company that will own both ClimateRock and GreenRock (“Pubco”) is expected to be listed on the Nasdaq Stock Market (“Nasdaq”) and will be led by Per Regnarsson, the Chief Executive Officer of both GreenRock and ClimateRock.

Key Points: 
  • Upon the closing of the business combination between ClimateRock and GreenRock contemplated by the Business Combination Agreement (the “Business Combination”), a holding company that will own both ClimateRock and GreenRock (“Pubco”) is expected to be listed on the Nasdaq Stock Market (“Nasdaq”) and will be led by Per Regnarsson, the Chief Executive Officer of both GreenRock and ClimateRock.
  • The terms of the Business Combination Agreement were negotiated by a fully-empowered special committee of independent directors of ClimateRock’s board of directors.
  • Per Regnarsson, Chief Executive Officer of GreenRock, commented, “The Business Combination will allow GreenRock to join forces with a strategic partner equally committed to shaping a sustainable future.
  • The description of the Business Combination provided here is only a summary and should be considered as qualified in its entirety by the Business Combination Agreement.

AUA, SUO Release Amendment to Non-Muscle Invasive Bladder Cancer Guideline

Retrieved on: 
Wednesday, January 24, 2024
Death, Guideline, Woman, Patient, American Urological Association, Bladder cancer, Partnership, Society, Combination, Diagnosis, BCG, Cystoscopy, Urine, Disease, AUA, SUO, NMIBC, Dietary supplement

BALTIMORE, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline amendment for the diagnosis and treatment of non-muscle invasive bladder cancer.

Key Points: 
  • BALTIMORE, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline amendment for the diagnosis and treatment of non-muscle invasive bladder cancer.
  • Bladder cancer continues to be a significant health issue in the United States, with non-muscle invasive bladder cancer (NMIBC) accounting for approximately 75% of the estimated 82,000 new cases diagnosed in 2023.
  • “One of the fastest growing spaces in Urologic Oncology is in the treatment of non-muscle invasive bladder cancer,” said Dr. Jeffrey M. Holzbeierlein, SUO president and chair for the guideline amendment.
  • Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment.